Slide 1: Second Quarter 2022 Financial Results & Business Update
Second Quarter 2022 Financial Results & Business Update July 27, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkerm
Slide 3: Agenda
Agenda Introduction Sandy Coombs, SVP, Investor Relations & Corporate Affairs Q2 2022 Financial Results Iain Brown, Chief Financial Officer Q2 2022 Commercial Review Todd Nichols, Chief Commercial Officer Business and R&D Pipeline Update Richard Pops, Chief Executive Officer
Slide 4: Q2 2022 Financial Results Summary
In millions In millions In millions Q2 2022 Financial Results Summary * Reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the Appendix of this presentation.
Slide 5: Second Quarter 2022 Revenue Summary
Second Quarter 2022 Revenue Summary Amounts in the table above may not sum due to rounding. *Inclusive of ARISTADA INITIO® **In Q2'22, royalty revenues from INVEGA SUSTENNA®/XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® (the “long-acting INVEGA products”) were $26.6 million, compar
Slide 6: Alkermes: 2022 Financial Expectations
Alkermes: 2022 Financial Expectations* *These expectations are provided by the Company on July 27, 2022 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. ‡Reconciliation of these non-GAAP financial measures to the most di
Slide 7: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations Q2’22 year-over-year net sales increased 9% to $96.1M Gross-to-net deductions: 51.1% in Q2’22, compared to 51.8 % in Q2’21 Inventory levels decreased sequentially by ~$1M, in line with typical seasonal patterns FY’22 net sales expected to range from $365M – $38
Slide 8: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations Q2’22 year-over-year net sales increased 3% to $74.6M Gross-to-net deductions: 54.2% in Q2’22, compared to 54.8% in Q2’21 Inventory levels decreased by ~$2M FY’22 net sales expected to range from $295M - $315M† Expect gross-to-net deductions of ~54% in FY’22 AR
Slide 9: ARISTADA Prescription Growth Trends
ARISTADA® Prescription Growth Trends Q2’22 year-over-year growth of 11% on TRx months of therapy (MOT) basis Outpaced overall atypical long-acting injectable (LAI) market Q2’22 year-over-year growth of 7% Market share: TRx MOT: 10% of atypical LAI market prescriptions in Q2’22 ARISTADA Quarterly TRx
Slide 10: LYBALVI Performance and Expectations
LYBALVI® Performance and Expectations LYBALVI Quarterly Net Sales ($M) † These expectations are provided by the Company on Jul. 27, 2022 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. Q2’22 net sales of $20.1M Gross-to
Slide 11: LYBALVI Prescription Growth Trends
LYBALVI® Prescription Growth Trends *Source: IQVIA NPA Weekly Q2’22 total TRx: ~17,000 ~4,260 prescribers had written a prescription for LYBALVI since launch
Slide 12: Appendix
Appendix Confidential, Internal Use Only
Slide 13: Appendix: Financial Results GAAP to Non-GAAP Adjustments
Appendix: Financial Results GAAP to Non-GAAP Adjustments
Slide 14: Appendix: 2022 Guidance GAAP to Non-GAAP Adjustments
Appendix: 2022 Guidance GAAP to Non-GAAP Adjustments Projected GAAP and non-GAAP measures reflect the mid-points within our financial expectations ranges.
Slide 15: www.alkermes.com
www.alkermes.com